吡咯烷二硫代氨基甲酸铵|T3147|TargetMol

Pyrrolidinedithiocarbamate ammonium
5108-96-3

￥286 100mg 起订

￥397 200mg 起订

￥672 500mg 起订

上海更新日期：2025-03-12

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 吡咯烷二硫代氨基甲酸铵

英文名称：: Pyrrolidinedithiocarbamate ammonium

CAS号：: 5108-96-3

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: ≥98%

产品类别：: 抑制剂

货号：: T3147

Product Introduction

Bioactivity

名称	Pyrrolidinedithiocarbamate ammonium
描述	Pyrrolidinedithiocarbamate ammonium (1-Pyrrolidinedithiocarboxylic acid ammonium salt), a selective NF-κB inhibitor, inhibits translation of nitric oxide synthase mRNA to prevent induction.
细胞实验	The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy's 5A medium supplemented with 10% fetal bovine serum. To study the effect of PDTC on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1b for 18 h. Various concentrations (3-1000 mM) of PDTC or its vehicle (culture medium) are added to the cells 30 min prior to IL-1b stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay, as described previously employing the multiple antibody sandwich principle that specifically detects human IL-8[1].
激酶实验	All binding studies are performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (with v) bovine serum albumin and 0.05% (v/v) Tween-20. For the PD-l-Ig/PD-Ll-His binding assay, inhibitors are pre-incubated with PD-Ll-His (10 nM final) for 15 m in 4 μL of assay buffer, followed by addition of PD-l-Ig (20 nM final) in 1 μL of assay buffer and further incubation for 15 m. PD-L1 from either human, cyno, or mouse are used. HTRF detection is achieved using europium crypate-labeled anti- Ig (1 nM final) and allophycocyanin (APC) labeled anti-His (20 nM final). Antibodies are diluted in HTRF detection buffer and 5 μL is dispensed on top of binding reaction. The reaction mixture is allowed to equilibrate for 30 minutes and signal (665 nm/620 nm ratio) is obtained using an En Vision fluorometer. Additional binding assays are established between PD-1-Ig/PD-L2-His (20, 5 nM, respectively), CD80-His/PD-Ll-Ig (100, 10 nM, respectively) and CD80-His/CTLA4-Ig (10, 5 nM, respectively).
体外活性	细胞预处理PDTC（3-1000 mM）剂量依赖性地减少IL-8产生。此外，PDTC（100 mM）抑制IL-8 mRNA的积累。PDTC通过抑制NF-kB DNA结合及其依赖的转录活性，从而阻止NF-kB的激活。综合我们的数据表明，通过PDTC抑制NF-kB可以降低肠上皮细胞IL-8的产生[1]。
体内活性	DSS+PDTC处理的第二组表现出抑制小肠长度缩短和DAI得分降低。该组中活化的NF-κB水平以及IL-1β和TNF-α水平显著低于对照组。这些发现表明，通过PDTC抑制NF-κB活性可以延缓由炎症引起的粘膜组织缺陷（侵蚀或溃疡）的愈合，但它能强烈抑制炎症细胞因子（IL-1β和TNF-α）的表达，从而显著缓解结肠炎。PDTC对于治疗溃疡性结肠炎具有重要价值[2]。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 75 mg/mL (456.51 mM) 5% DMSO+95% Saline : 0.6 mg/mL (3.65 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
关键字	TNF-α \| Inhibitor \| 1-Pyrrolidinedithiocarboxylic acid ammonium \| Nuclear factor-κB \| inhibit \| NF-κB \| Pyrrolidinedithiocarbamate ammonium \| ulcerative \| inflammation \| IL-1β \| colitis \| Nuclear factor-kappaB
相关产品	Lidocaine hydrochloride \| sodium lauroyl-α-hydroxyethyl sulfonate \| Sodium Houttuyfonate \| Lidocaine \| 5-Aminosalicylic Acid \| Diallyl disulfide \| Glucosamine \| Sodium salicylate \| α-Lipoic Acid \| Zingerone \| Indole-3-carbinol \| Diethylmaleate
相关库	抑制剂库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 抗衰老化合物库 \| 药物功能重定位化合物库 \| 抗癌药物库

吡咯烷二硫代甲酸铵|||吡咯烷二硫代氨基甲酸铵|||Pyrrolidinedithiocarbamate|||PDTC|||APDC|||Ammonium pyrrolidinedithiocarbamate|||1-Pyrrolidinedithiocarboxylic acid ammonium salt|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子